Neuren Media and Analyst Coverage, page-1791

Neuren Pharmaceuticals (NEU)
Neuren Pharmaceuticals is a drug
development company with two
key rare disease assets: 1) the
commercially available treatment
Daybue (trofinetide), which will
continue to provide ongoing royalty/
milestone income to NEU; and 2)
NNZ-2591, which is undergoing clinical
development and will commence its
first Phase 3 trial in “mid CY25”.
With A$341m cash and no debt as of
31-March-2025, we remain confident
NEU will be able to fund multiple
Phase 3 trials and recruit the 160
subjects for the first Phase 3 trial
relatively smoothly. We view NNZ-2591
as the key value driver for NEU and
remain optimistic about its prospects
for success following promising Phase
2 data. As the Phase 3 trial proceeds
through recruitment across CY25-26,
we expect the share price to further
appreciate as the readout draws
nearer.
Buy, Price Target $20.00